Cannabis oil may reduce the duration and frequency of spasms caused by benign essential blepharospasm (eye twitching), researchers say. The treatment could serve as a second-line treatment for ...

The FDA has approved Xeomin (incobotulinumtoxinA; Merz) as a first-line treatment for blepharospasm in adults. The Food and Drug Administration (FDA) has approved Xeomin (incobotulinumtoxinA; Merz) as ...

CORONADO, California — Patients with blepharospasm can wait more than 2 years to receive a correct diagnosis, according to a new survey. "There's no excuse," said researcher Kristen Dunbar, MD, a ...

Blepharospasm is a condition that is characterized by involuntary movements of the eyelids. Tics and twitches around the eye area are common, but in severe cases this can inhibit the ability of an ...

RALEIGH, N.C.--(BUSINESS WIRE)--Merz Americas announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for XEOMIN ® ...

Blepharospasm, also referred to as benign essential blepharospasm, is a rare condition that possibly goes undiagnosed or misdiagnosed. Botulinum toxin is the only FDA -approved medication for the ...

Please provide your email address to receive an email when new articles are posted on . By becoming familiar with ocular conditions that often accompany movement disorders, ophthalmologists are better ...

COURTESY OF DR. RICHARD HESSE, OSHNER CLINIC. Blepharospasm and facial dystonia have been present since at least the 16th century when Pieter Breughel painted the man in Figure 1, but any useful ...

A fascinating new study published in the latest edition of Movements Disorders (Vol.00 No.00, 2016) presents two patient case studies that demonstrate how speaking French as a second language can ...

Merz Pharmaceuticals today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Xeomin® (incobotulinumtoxinA), a botulinum toxin type A for the treatment of adults ...